73.48MMarket Cap-4.05P/E (TTM)
2.190High1.970Low128.15KVolume2.040Open1.985Pre Close269.33KTurnover0.51%Turnover RatioLossP/E (Static)34.66MShares55.00052wk High26.84P/B53.67MFloat Cap1.07852wk Low--Dividend TTM25.32MShs Float55.000Historical High--Div YieldTTM11.08%Amplitude1.078Historical Low2.101Avg Price1Lot Size
FibroBiologics Stock Forum
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing
Monday, 30th December at 4:30 pm
HOUSTON, Dec. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has closed the second $5...
Yorkville agreed to advance to FibroBiologics the first $15 million available und...
FibroBiologics Announces $25 Million Financing
Monday, 23rd December at 7:55 am
HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has entered into a Standby Equity Purchase Agreement (th...
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
FibroBiologics (Nasdaq: FBLG) has filed a patent application for methods using fibroblasts and Tissue Factor-expressing cells to prevent IBMIR-mediated blood clotting in cell therapy treatments. The technology aims to address a major challenge in cell therapy by reducing inflammatory and coagulative...
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
FibroBiologics (Nasdaq: FBLG) reported promising results from its artificial thymus organoid program. The technology demonstrated that fibroblasts and thymus-derived cell organoids can maintain functionality for over 50 days after transplantation, showing vascularization and generating diverse mature T cells in animal models. The organoids produced fully mature T cells with various diff...
FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology
No comment yet